Loading...
Pivotal new studies and updates of previously reported studies, some potentially practice changing, were presented at this year's European Society for Medical Oncology (ESMO) Congress held September 13–17 in Barcelona, Spain. Here, NEJM Journal Watch Oncology and Hematology Associate Editor David Ilson reviews some of the key presentations in GI cancers.
Two important trials evaluated preoperative immune checkpoint inhibitor therapy for patients with mismatch repair protein deficient (dMMR)/microsatellite instability (MSI)–high colon cancer.
Researchers reported updated 3-year disease-free survival (DFS) results from the industry-sponsored NICHE-2 trial (abstract LBA24). Patients with locally advanced dMMR colon cancer…